Hepatitis C virus-associated and metabolic steatosis. Different or overlapping diseases?;Steatosi associata al virus dell'epatite C e steatosi metabolica. Patologie diverse o sovrapposte?

Annali Italiani di Medicina Interna

Volumn 20, Issue 1, 2005, Pages 10-22

  Lonardo, Amedeo ^a   Loria, Paola ^b   Adinolfi, Luigi E ^c   Andreana, Augusto ^c   Ruggiero, Giuseppe ^c   Carulli, Nicola ^b  

^a Ospedale Civile   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Hepatitis C virus; Hyperlipidemia; Insulin resistance; Iron; Nonalcoholic fatty liver disease; Steatosis; Type 2 diabetes mellitus

Indexed keywords

FATTY LIVER; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; METABOLIC DISORDER; REVIEW; VIROLOGY;

FATTY LIVER; HEPACIVIRUS; HEPATITIS C; HUMANS; METABOLIC DISEASES;

EID: 33644666754     PISSN: 03939340     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (189)

1. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Non-alcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434-8.
2. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002; 122: 1649-57.
3. Byron D, Minuk GY. Clinical hepatology: profile of an urban, hospital-based practice. Hepatology 1996; 24: 813-5.
4. Brunt EM. Nonalcoholic steatohepatitis. Semin Liver Dis 2004; 24: 3-20.
5. Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 2001; 21: 17-26.
6. Contos MJ, Sanyal AJ. The clinicopathologic spectrum and management of nonalcoholic fatty liver disease. Adv Anat Pathol 2002; 9: 37-51.
7. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52.
8. Malhotra V, Sakhuja P, Gondal R, Sarin SK, Siddhu M, Dutt N. Histological comparison of chronic hepatitis B and C in an Indian population. Trop Gastroenterol 2000; 21: 20-1.
9. Loria P, Lonardo A, Leonardi F, et al. Non-organ specific autoantibodies in nonalcoholic fatty liver disease: prevalence and correlates. Dig Dis Sci 2003; 48: 1-9.
10. Giusti G, Pasquale G, Galante D, et al. Clinical and histological aspects of chronic HCV infection and cirrhosis. Hepatogastroenterology 1993; 40: 365-9.
11. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 1358-64.
12. Ohata K, Hamasaki K, Toriyama K, et al. Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Cancer 2003; 97: 3036-43.
13. Sanyal AJ, Contos MJ, Sterling RK, et al. Nonalcoholic fatty liver disease in patients with hepatitis C is associated with features of the metabolic syndrome. Am J Gastroenterol 2003; 98: 2064-71.
14. Poynard T, Ratziu V, McHutchinson J, et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003; 38: 75-85.
15. Ratziu V, Trabut JB, Poynard T. Fat, diabetes, and liver injury in chronic hepatitis C. Curr Gastroenterol Rep 2004; 6: 22-9.
16. Farinati F, Cardin R, De Maria N, et al. Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis. J Hepatol 1995; 22: 449-56.
17. Moriya K, Fujie H, Shintani Y, et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 1998; 4: 1065-7.
18. Perlemuter G, Sabile A, Brechot C. Interactions between hepatitis C virus and hepatic lipid metabolism. Gastroenterol Clin Biol 2000; 24: 547-53.
19. Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120: 1183-92.
20. Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 2001; 21: 27-41.
21. Pessayre D, Berson A, Fromenty B, Mansouri A. Mitochondria in steatohepatitis. Semin Liver Dis 2001; 21: 57-69.
22. Robertson G, Leclercq I, Farrell GC. Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress. Am J Physiol Gastrointest Liver Physiol 2001; 281: 1135-9.
23. Neuschwander-Tetri BA. A resistance movement in NASH. Am J Gastroenterol 2001; 96: 2813-4.
24. Reid EA. Nonalcoholic steatohepatitis. Gastroenterology 2001; 121: 710-23.
25. Marchesini G, Forlani G. NASH: from liver diseases to metabolic disorders and back to clinical hepatology. Hepatology 2002; 35: 497-9.
26. Czaja AJ, Homburger HA. Autoantibodies in liver disease. Gastroenterology 2001; 120: 239-49.
27. Cacoub P, Renou C, Rosenthal E, et al. Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. Medicine 2000; 79: 47-56.
28. Mehta S, Levey JM, Bonkovsky HL. Extrahepatic manifestations of infection with hepatitis C virus. Clin Liver Dis 2001; 5: 979-1008.
29. Lonardo A, Loria P, Carulli N. Concurrent non-alcoholic steatohepatitis and psoriasis. Report of three cases from the POLISTENA study. Dig Liver Dis 2001; 33: 86-7.
30. Adinolfi LE, Utili R, Attanasio V, et al. Epidemiology, clinical spectrum and prognostic value of mixed cryoglobulinaemia in hepatitis C virus patients: a prospective study. Ital J Gastroenterol 1996; 28: 1-9.
31. Alberti A, Noventa F, Benvegnu L, Boccato S, Gatta A. Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection. Ann Intern Med 2002; 137: 961-4.
32. Puoti C, Castellacci R, Montagnese F, et al. Histological and virological features and follow-up of hepatitis C virus carriers with normal aminotransferase levels: the Italian prospective study of the asymptomatic C carriers (ISAAC). J Hepatol 2002; 37: 117-23.
33. Mofrad P, Contos MJ, Haque M, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003; 37: 1286-92.
34. Czaja AJ. Recurrence of nonalcoholic steatohepatitis after liver transplantation. Liver Transpl Surg 1997; 3: 185-6.
35. El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 2002; 36 (Suppl 1): S74-S83.
36. Sorensen HT, Mellemkjaer L, Jepsen P, et al. Risk of cancer in patients hospitalized with fatty liver: a Danish cohort study. J Clin Gastroenterol 2003; 36: 356-9.
37. Ong JP, Younossi ZM. Is hepatocellular carcinoma part of the natural history of nonalcoholic steatohepatitis? Gastroenterology 2002; 123: 375-8.
38. Adinolfi LE, Utili R, Ruggiero G. Body composition and hepatic steatosis as precursors of fibrosis in chronic hepatitis C patients. Hepatology 1999; 30: 1530-1.
39. Cimino L, Oriani G, D'Arienzo A, et al. Interactions between metabolic disorders (diabetes, gallstones, and dyslipidaemia) and the progression of chronic hepatitis C virus infection to cirrhosis and hepatocellular carcinoma. A cross-sectional multicentre survey. Dig Liver Dis 2001; 33: 240-6.
40. Lonardo A, Loria P. Is insulin resistance a pathogenic co-factor in hepatitis C virus-related disease and hepatocellular carcinoma [letter]? Dig Liver Dis 2002; 34: 151.
41. Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology 2004; 126: 586-97.
42. Nomura H, Kashiwagi S, Hayashi J, Kajiyama W, Tani S, Goto M. Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn J Med 1988; 27: 142-9.
43. Matsuura K, Tobe K, Tsuji T. Fatty liver and obesity in university students. Nippon Shokakibyo Gakkai Zasshi 1995; 92: 1743-5.
44. Lonardo A, Bellini M, Tartoni M, Tondelli E. The bright liver syndrome. Prevalence and determinants of a "bright" liver echopattern. Ital J Gastroenterol Hepatol 1997; 29: 351-6.
45. Bellentani S, Tiribelli C. The spectrum of liver disease in the general population: lesson from the Dionysos study. J Hepatol 2001; 35: 531-7.
46. Loria P, Lonardo A, Lombardini S, et al. Epidemiologia e storia naturale dell'epatopatia steatosica non alcolica. Ann Ital Med Int 2003; 18 (Suppl 1): 15S-31S.
47. Naveau S, Giraud V, Borotto E, Aubert A, Capron F, Chaput JC. Excess weight risk factor for alcoholic liver disease. Hepatology 1997; 25: 108-11.
48. Bellentani S, Saccoccio G, Masutti F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000; 132: 112-7.
49. Monto A, Alonzo J, Watson JJ, Grunfeld C, Wright TL. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology 2002; 36: 729-36.
50. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556-62.
51. Stroffolini T, Menchinelli M, Taliani G, et al. High prevalence of hepatitis C virus infection in a small central Italian town: lack of evidence of parenteral exposure. Ital J Gastroenterol 1995; 27: 235-8.
52. Osella AR, Misciagna G, Leone A, Di Leo A, Fiore G. Epidemiology of hepatitis C virus infection in an area of Southern Italy. J Hepatol 1997; 27: 30-5.
53. Lin SC, Shih SC, Kao CR, Chou SY. Prevalence of antibodies to hepatitis C virus in patients with nonalcoholic fatty liver. Zhonghua Yi Xue Za Zhi 1995; 56: 80-5.
54. Day CP. Pathogenesis of steatohepatitis. Best Pract Res Clin Gastroenterol 2002; 16: 663-78.
55. Pagano G, Pacini G, Musso G, et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 2002; 35: 367-72.
56. Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107: 450-5.
57. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50: 1844-50.
58. Lonardo A. Fatty liver and nonalcoholic steatohepatitis. Where do we stand and where are we going? Dig Dis 1999; 17: 80-9.
59. Knobler H, Schattner A, Zhornicki T, et al. Fatty liver - an additional and treatable feature of the insulin resistance syndrome. QJM 1999; 9: 73-9.
60. Cortez-Pinto H, Camino ME, Baptista A, De Oliveira AG, De Moura MC. Non-alcoholic fatty liver: another feature of the metabolic syndrome? Clin Nutr 1999; 18: 353-8.
61. Marceau P, Biron S, Hould FS, et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 1999; 84: 1513-7.
62. Tankurt E, Biberoglu S, Ellidkuz E, et al. Hyperinsulinemia and insulin resistance in non-alcoholic steatohepatitis. J Hepatol 1999; 31: 963.
63. Macdonald GA, Powell LW. More clues to the relationship between hepatic iron and steatosis: an association with insulin resistance? Gastroenterology 1999; 117: 1241-4.
64. Sanyal AJ. Insulin resistance and nonalcoholic steatohepatitis: fat or fiction? Am J Gastroenterol 2001; 96: 274-6.
65. Unger RH. Lipotoxic diseases. Annu Rev Med 2002; 53: 319-36.
66. Poitout V, Robertson RP. Minireview: secondary beta-cell failure in type 2 diabetes - a convergence of glucotoxicity and lipotoxicity. Endocrinology 2002; 143: 339-42.
67. Vague J. The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. Am J Clin Nutr 1956; 4: 20-34.
68. Sonnichsen AC, Ritter MM, Mohrle W, Richter WO, Schwandt P. The waist-to-hip ratio corrected for body mass index is related to serum triglycerides and high-density lipoprotein cholesterol but not to parameters of glucose metabolism in healthy premenopausal women. Clin Investig 1993; 71: 913-7.
69. Hsieh SD, Yoshinaga H, Muto T, Sakurai Y. Regular physical activity and coronary risk factors in Japanese men. Circulation 1998; 97: 661-5.
70. Lonardo A, Trande P. Are there any sex differences in fatty liver? A study of glucose metabolism and body fat distribution. J Gastroenterol Hepatol 2000; 15: 775-82.
71. Song S. The role of increased liver triglyceride content: a culprit of diabetic hyperglycaemia? Diabetes Metab Res Rev 2002; 18: 5-12.
72. Seip M, Trygstad O. Generalized lipodystrophy, congenital and acquired (lipoatrophy). Acta Paediatr Suppl 1996; 413: 2-28.
73. Moitra J, Mason MM, Olive M, et al. Life without white fat: a transgenic mouse. Genes Dev 1998; 12: 3168-81.
74. Shimomura I, Hammer RE, Richardson JA, et al. Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy. Genes Dev 1998; 12: 3182-94.
75. Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 7: 941-6.
76. Gavrilova O, Marcus-Samuels B, Graham D, et al. Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. J Clin Invest 2000; 105: 271-8.
77. Shimomura I, Hammer RE, Ikemoto S, Brown MS, Goldstein JL. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 1999; 401: 73-6.
78. Boden G. Pathogenesis of type 2 diabetes. Insulin resistance. Endocrinol Metab Clin North Am 2001; 30: 801-15.
79. Boden G, Shulman GI. Free fatty acids in obesity and type 2 diabetes mellitus: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Invest 2002; 32 (Suppl 3): 14-23.
80. Chitturi S, Abeygunasekera S, Farrell GC, et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35: 373-9.
81. Paradis V, Perlemuter G, Bonvoust F, et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in the progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 2001; 34: 738-44.
82. Banerji MA, Buckley MC, Chaiken RL, Gordon D, Lebovitz HE, Kral JG. Liver fat, serum triglycerides and visceral adipose tissue in insulin-sensitive and insulin-resistant black men with NIDDM. Int J Obes Relat Metab Disord 1995; 19: 846-50.
83. Lonardo A, Loria P, Carulli N. Insulin resistance in nonalcoholic fatty liver disease. A clinical perspective. In: Leuschner U, James O, Dancygier H, eds. Steatohepatitis (NASH and ASH). Dordrecht/Boston/London: Kluwer Academic Publishers, 2001: 104-13.
84. Okamoto M, Takeda Y, Yoda Y, Kobaayashi K, Fujino MA, Yamagata Z. The association of fatty liver and diabetes risk. J Epidemiol 2003; 13: 15-21.
85. Hadziyannis SJ. The spectrum of extrahepatic manifestations in hepatitis C virus infection. J Viral Hepatol 1997; 4: 9-28.
86. Hadziyannis SJ, Karamanos B. Diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999; 29: 604-5.
87. Mason AL, Lau JY, Hoang N, et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999; 29: 328-33.
88. Labropoulou-Karatza C, Goritsas C, Fragopanagou H, Repandi M, Matsouka P, Alexandrides T. High prevalence of diabetes mellitus among adult beta-thalassemic patients with chronic hepatitis C. Eur J Gastroenterol Hepatol 1999; 11: 1033-6.
89. Knobler H, Schihmanter R, Zifroni A, Fenakel G, Schattner A. Increased risk of type 2 diabetes in noncirrhotic patients with chronic hepatitis C virus infection. Mayo Clin Proc 2000; 75: 355-9.
90. Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 2000; 133: 592-9.
91. Alexander GJ. An association between hepatitis C virus infection and type 2 diabetes mellitus: what is the connection? Ann Intern Med 2000; 133: 650-2.
92. Kirk GD, de Sanjose S, Ott M. Impact of race on the association between diabetes and HCV [letter]. Am J Gastroenterol 2004; 99: 564.
93. Mehta SH, Brancati FL, Strathdee SA, et al. Hepatitis C virus infection and incident type 2 diabetes. Hepatology 2003; 38: 50-6.
94. Zignego AL, Ferri C, Giannini C, et al. Hepatitis C virus genotype analysis in patients with type II mixed cryoglobulinemia. Ann Intern Med 1996; 124: 31-4.
95. Andreone P, Gramenzi A, Cursaro C, Bernardi M, Zignego AL. Monoclonal gammopathy in patients with chronic hepatitis C virus infection [letter]. Blood 1996; 88: 1122.
96. Sud A, Hui JM, Farrell GC, et al. Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index. Hepatology 2004; 39: 1239-47.
97. Adinolfi LE, Loria P, Lonardo A, Carulli N, Ruggiero G. Metabolic alterations in HCV-associated steatosis and in NAFLD: a comparison study [abstract]. J Hepatol 2003; 38 (Supp 2): 122A.
98. Rubbia-Brandt L, Fabris P, Paganin S, et al. Steatosis affects chronic hepatitis C progression in a genotype specific way. Gut 2004; 53: 406-12.
99. Adinolfi LE, Mangoni ED, Andreana A. Interferon and ribavirin treatment for chronic hepatitis C may activate celiac disease [letter]. Am J Gastroenterol 2001; 96: 607-8.
100. Lonardo A, Loria P, Leonardi F, et al. Fasting insulin and uric acid levels but not indices of iron metabolism are independent predictors of nonalcoholic fatty liver disease. A case-control study. Dig Liver Dis 2002; 34: 204-11.
101. Sharma P, Balan V, Hernandez J, et al. Hepatic steatosis in hepatitis C virus genotype 3 infection: does it correlate with body mass index, fibrosis, and HCV risk factors? Dig Dis Sci 2004; 49: 25-9.
102. Clouston AD, Jonsson JR, Purdie DM, et al. Steatosis and chronic hepatitis C. Analysis of fibrosis and stellate cell activation. J Hepatol 2001; 34: 314-20.
103. Westin J, Nordlinder H, Lagging M, Norkrans G, Westjal R. Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. J Hepatol 2002; 37: 837-42.
104. Adinolfi LE, Utili R, Andreana A, et al. Serum HCV serum levels correlate with histological liver damage and concur with steatosis in progression of chronic hepatitis C. Dig Dis Sci 2001; 46: 1677-83.
105. Castèra L, Hèzode C, Roudot-Thoraval F, et al. Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. Gut 2003; 52: 288-92.
106. Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann Intern Med 2004; 140: 370-81.
107. Hickman IJ, Clouston AD, Macdonald GA, et al. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut 2002; 51: 89-94.
108. Hickman IJ, Jonsson JR, Prins JB, et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 2004; 53: 413-9.
109. Kumar D, Farrell GC, Fung C, George J. Hepatitis C virus genotype 3 is cytopathic to hepatocytes: reversal of hepatic steatosis after sustained therapeutic response. Hepatology 2002; 36: 1266-72.
110. Assy N, Kaita K, Mymin D, Levy C, Rosser B, Minuk G. Fatty infiltration of liver in hyperlipidemic patients. Dig Dis Sci 2000; 45: 1929-34.
111. Koruk M, Savas MC, Yilmaz O, et al. Serum lipids, lipoproteins and apolipoproteins levels in patients with nonalcoholic steatohepatitis. J Clin Gastroenterol 2003; 37: 177-82.
112. Lonardo A, Loria P. Apolipoprotein synthesis in nonalcoholic steatohepatitis [letter]. Hepatology 2002; 36: 514-5.
113. Tarugi P, Lonardo A, Ballarini G, et al. Fatty liver in heterozygous hypobetalipoproteinemia caused by a novel truncated form of apolipoprotein B. Gastroenterology 1996; 111: 1125-33.
114. Tarugi P, Lonardo A, Gabelli C, et al. Phenotypic expression of familial hypobetalipoproteinemia in three kindreds with mutations of apolipoprotein B gene. J Lipid Res 2001; 42: 1552-61.
115. Bernard S, Touzet S, Personne I, et al. Association between microsomal triglyceride transfer protein gene polymorphism and the biological features of liver steatosis in patients with type II diabetes. Diabetologia 2000; 43: 995-9.
116. Serfaty L, Andreani T, Giral P, Carbonell N, Chazouilliers O, Poupon R. Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J Hepatol 2001; 34: 428-34.
117. Petit JM, Benichou M, Duvillard L, et al. Hepatitis C virus-associated hypobetalipoproteinemia is correlated with plasma viral load, steatosis, and liver fibrosis. Am J Gastroenterol 2003; 98: 1150-4.
118. Hofer H, Bankl HC, Wrba F, et al. Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3a. Am J Gastroenterol 2002; 97: 2880-5.
119. Thomssen R, Bonk S, Propfe C, Heermann KH, Kochel HG, Uy A. Association of hepatitis C virus in human sera with betalipoprotein. Med Microbiol Immunol 1992; 181: 293-300.
120. Monazahian M, Bohme I, Bonk S, et al. Low density lipoprotein receptor as a candidate receptor for hepatitis C virus. J Med Virol 1999; 57: 223-9.
121. Adinolfi LE, Ingrosso D, Cesaro G, Cimmino A, Zappia V, Ruggiero G. Hyperhomocysteinemia and methylentetrahydrofolate reductase C677T polymorphism promote steatosis and fibrosis in chronic hepatitis C patients. Hepatology 2005, in press.
122. Bugianesi E, Manzini P, D'Antico S, et al. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology 2004; 39: 179-87.
123. Loria P, Lonardo A, Carulli N. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver [letter]. Hepatology 2004; 39: 1748.
124. Facchini FS, Hua NW, Stoohs RA. Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of non-alcoholic fatty liver disease. Gastroenterology 2002; 122: 931-9.
125. Fernandez-Real JM, Penarroja G, Castro A, Garcia-Bragado F, Hernandez-Aguado I, Ricart W. Blood letting in high-ferritin type 2 diabetes: effects on insulin sensitivity and beta-cell function. Diabetes 2002; 51: 1000-4.
126. Facchini FS. Near-iron deficiency-induced remission of gouty arthritis. Rheumatology 2003; 42: 1-6.
127. Pietrangelo A. Hemochromatosis gene modifies course of hepatitis C viral infection. Gastroenterology 2003; 124: 1509-23.
128. Kakizaki S, Takagi H, Horiguchi N, et al. Iron enhances hepatitis C virus replication in cultured human hepatocytes. Liver 2000; 20: 125-8.
129. Riggio O, Montagnese F, Fiore P, et al. Iron overload in patients with chronic viral hepatitis: how common is it? Am J Gastroenterol 1997; 92: 1298-301.
130. Thorburn D, Curry G, Spooner R, et al. The role of iron and haemochromatosis gene mutations in the progression of liver disease in chronic hepatitis C. Gut 2002; 50: 248-52.
131. Kageyama F, Kobayashi Y, Kawasaki T, Toyokuni S, Uchida K, Nakamura H. Successful interferon therapy reverses enhanced hepatic iron accumulation and lipid peroxidation in chronic hepatitis C. Am J Gastroenterol 2000; 95: 1041-50.
132. Fernandez-Real JM, Ricart-Engel W, Arroyo E, et al. Serum ferritin as a component of the insulin resistance syndrome. Diabetes Care 1998; 21: 62-8.
133. Ikai E, Honda R, Yamada Y. Serum gamma-glutamyl transpeptidase level and blood pressure in nondrinkers: a possible pathogenetic role of fatty liver in obesity-related hypertension. J Hum Hypertens 1994; 8: 95-100.
134. Akahoshi M, Amasaki Y, Soda M, et al. Correlation between fatty liver and coronary risk factors: a population study of elderly men and women in Nagasaki, Japan. Hypertens Res 2001; 24: 337-43.
135. Donati G, Stagni B, Piscaglia F, et al. Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance. Gut 2004; 53: 1020-3.
136. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001; 121: 91-100.
137. Ferrannini E. Insulin resistance, iron, and the liver. Lancet 2000; 355: 2181-2.
138. Festa A, D'Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102: 42-7.
139. Ishizaka N, Ishizaka Y, Takahashi E, et al. Association between hepatitis C virus sieropositivity, carotid-artery plaque, and intima-media thickening. Lancet 2002; 359: 133-5.
140. Letteron P, Fromenty B, Terris B, Degott C, Pessayre D. Acute and chronic hepatic steatosis lead to in vivo lipid peroxidation in mice. J Hepatol 1996; 24: 200-8.
141. Farinati F, Cardin R, Degan P, et al. Oxidative DNA damage in circulating leukocytes occurs as an early event in chronic HCV infection. Free Radic Biol Med 1999; 27: 1284-91.
142. Okuda M, Li K, Beard MR, et al. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 2002; 122: 366-75.
143. Lerat H, Honda M, Beard MR, et al. Steatosis and liver cancer in transgenic mice expressing the structural and non-structural proteins of hepatitis C virus. Gastroenterology 2002; 122: 352-65.
144. Angulo P, Lindor KD. Treatment of nonalcoholic fatty liver: present and emerging therapies. Semin Liver Dis 2001; 21: 81-8.
145. Sanyal AJ, for the American Gastroenterological Association. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 1705-25.
146. Oneta CM, Dufour JF. Non-alcoholic fatty liver disease: treatment options based on pathogenic considerations. Swiss Med Wkly 2002; 132: 493-505.
147. Angulo P. Current best treatment for non-alcoholic fatty liver disease. Expert Opin Pharmacother 2003; 4: 611-23.
148. Eriksson S, Eriksson K, Bondesson L. Nonalcoholic steatohepatitis in obese: a reversible condition. Acta Med Scand 1986; 220: 83-8.
149. Keeffe EB, Adesman PW, Stenzel P, Palmer RM. Steatosis and cirrhosis in an obese diabetic. Resolution of fatty liver by fasting. Dig Dis Sci 1987; 32: 441-5.
150. Vajro P, Fontanella A, Perna C, Orso G, Tedesco M, De Vincenzo A. Persistent hyperaminotransferasemia resolving after weight reduction in obese children. J Pediatr 1994; 125: 239-41.
151. Ueno T, Sugawara H, Sujaku K, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997; 27: 103-7.
152. Musso G, Gambino R, De Michieli F, et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 2003; 37: 909-16.
153. Rivellese AA, Lilli S. Quality of dietary fatty acids, insulin sensitivity and type 2 diabetes. Biomed Pharmacother 2003; 57: 84-7.
154. Abdelmalek MF, Angulo P, Jorgensen RA, Sylvestre PB, Lindor KD. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol 2001; 96: 2711-7.
155. Miglio F, Rovati LC, Santoro A, Setnikar I. Efficacy and safety of oral betaine glucuronate in non-alcoholic steatohepatitis. A double-blind, randomized, parallel-group, placebo-controlled prospective clinical study. Arzneimittelforschung 2000; 50: 722-7.
156. Laurin J, Lindor K, Crippin J, et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 1996; 23: 1464-7.
157. Vajro P, Franzese A, Valerio G, Iannucci MP, Aragione N. Lack of efficacy of ursodeoxycholic acid for the treatment of liver abnormalities in obese children. J Pediatr 2000; 136: 739-43.
158. Lindor KD, Kowdley KV, Heathcote EJ, et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004; 39: 770-8.
159. Bauditz J, Schmidt HH, Dippe P, Lochs H, Pirlich M. Non-alcohol induced steatohepatitis in non-obese patients: treatment with ursodeoxycholic acid. Am J Gastroenterol 2004; 99: 959-60.
160. Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr 2000; 136: 734-8.
161. Hasegawa T, Yoneda M, Nakamura K, Makino I, Terano A. Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther 2001; 15: 1667-72.
162. Kugelmans M, Hill DB, Vivian B, Marsano L, McClain CJ. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 2003; 38: 413-9.
163. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet 2001; 358: 893-4.
164. Nair S, Diehl AM, Wiseman M, Farr GH Jr, Perrillo RP. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther 2004; 20: 23-8.
165. Caldwell SH, Hespenheide EE, Redick JA, Iezzoni JC, Battle EH, Sheppard BL. A pilot study of thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 2001; 96: 519-25.
166. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003; 38: 1008-17.
167. Promrat K, Lutchman G, Uwaifo GI, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004; 39: 188-96.
168. Merat S, Malekzadeh R, Sohrabi MR, et al. Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomized controlled study. J Hepatol 2003; 38: 414-8.
169. Harrison SA, Ramrakhiani S, Brunt EM, Anbari MA, Cortese C, Bacon BR. Orlistat in the treatment of NASH: a case series. Am J Gastroenterol 2003; 98: 926-30.
170. Tanaka K, Kondo M, Sakaguchi T, et al. Efficacy of ursodeoxycholic acid in combination with interferon-alpha in treating chronic hepatitis C: results of a long-term follow-up trial. J Gastroenterol Hepatol 1996; 11: 1155-60.
171. Lirussi F, Beccarello A, Bortolato L, et al. Long-term treatment of chronic hepatitis C with ursodeoxycholic acid: influence of HCV genotypes and severity of liver disease. Liver 1999; 19: 381-8.
172. Look MP, Gerard A, Rao GS, et al. Interferon/antioxidant combination therapy for chronic hepatitis C: a controlled pilot trial. Antiviral Res 1999; 43: 113-22.
173. Ideo G, Bellobuono A, Tempini S, et al. Antioxidant drugs combined with alpha-interferon in chronic hepatitis C not responsive to alpha-interferon alone: a randomized, multicentre study. Eur J Gastroenterol Hepatol 1999; 11: 1203-7.
174. Mahmood S, Yamada G, Niiyama G, et al. Effect of vitamin E on serum aminotransferase and thioredoxin levels in patients with viral hepatitis C. Free Radic Res 2003; 37: 781-5.
175. Beloqui O, Prieto J, Suarez M, et al. N-acetyl cysteine enhances the response to interferon-alpha in chronic hepatitis C: a pilot study. J Interferon Res 1993; 13: 279-82.
176. Grant PR, Black A, Garcia N, Prieto J, Garson JA. Combination therapy with interferon-alpha plus N-acetyl cysteine for chronic hepatitis C: a placebo controlled double-blind multicentre study. J Med Virol 2000; 61: 439-42.
177. Neri S, Ierna D, Antoci S, Campanile E, D'Amico RA, Noto R. Association of alpha-interferon and acetyl cysteine in patients with chronic C hepatitis. Panminerva Med 2000; 42: 187-92.
178. Sartori M, Andorno S, Rigamonti C, Boldorini R. Chronic hepatitis C treated with phlebotomy alone: biochemical and histological outcome. Dig Liver Dis 2001; 33: 157-62.
179. Fargion S, Fracanzani AL, Rossini A, et al. Iron reduction and sustained response to interferon-alpha therapy in patients with chronic hepatitis C: results of an Italian multicenter randomized study. Am J Gastroenterol 2002; 97: 1204-10.
180. Furutani M, Nakashima T, Sumida Y, et al. Insulin resistance/ beta-cell function and serum ferritin level in non-diabetic patients with hepatitis C virus infection. Liver Int 2003; 23: 294-9.
181. Valenti L, Fracanzani AL, Fargion S. Effect of iron depletion in patients with nonalcoholic fatty liver disease without carbohydrate intolerance. Gastroenterology 2003; 124: 866-7.
182. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ. The fat-derived hormone adiponectin alleviates alcoholic and non-alcoholic fatty liver diseases in mice. J Clin Invest 2003; 112: 91-100.
183. Kusunoki M, Tsutsumi K, Hara T, et al. Correlation between lipid and glycogen contents in liver and insulin resistance in high-fat-fed rats treated with the lipoprotein lipase activator NO-1886. Metabolism 2002; 51: 792-5.
184. Gochee PA, Jonsson JR, Clouston AD, Pandeya N, Purdie DM, Powell EE.
185. Li Z, Yang S, Lin H, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003; 37: 343-50.
186. Hundal RS, Petersen KF, Mayerson AB, et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 2002; 109: 1321-6.
187. Kim JK, Kim YJ, Fillmore JJ, et al. Prevention of fat-induced insulin resistance by salicylate. J Clin Invest 2001; 108: 437-46.
188. Negro F. Hepatitis C virus and liver steatosis: when fat is not beautiful. J Hepatol 2004; 40: 533-5.
189. McCullough AJ. Obesity and its nurturing effect on hepatitis C. Hepatology 2003; 38: 557-9.